Emollients cost-effective treatment for patients with Atopic Dermatitis: Study
The follow-up of Atopic dermatitis (AD) and relapses have a great impact on patient's quality of life, expenditures and social costs. A recent comparative study suggests treatment with preventive emollient was a cost-effective option compared with no treatment in adult AD patients. The research has been published in the journal Clinical, Cosmetic and Investigational Dermatology on December 21, 2020.
Atopic dermatitis (AD) is an inflammatory skin condition affecting between 5 and 20% of children. This disease mostly recovers by itself at adulthood in 85% of cases. In industrialised countries, the prevalence of AD has tripled in the last 30 years. AD relapses are prevented by the daily use of a moisturiser. Thus, NICE recommends moisturisers as the first-line of treatment in delaying flare-ups, and corticoids to treat acute phases. Nevertheless, this therapy aims only to manage the symptoms. It improves the quality of life by decreasing the frequency and the intensity of flare-ups, the number of visits to a doctor, and the loss of productivity. While a collection of emollient (moisturiser) floods the market, their efficiency is not well known. Only few cost-effectiveness studies have been published and none were comparing an overall set of emollients. For this purpose, researchers of France conducted a study to assess the cost-effectiveness of different emollients prescribed to AD patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.